NCT02252406

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

Impact of Ranolazine on Inflammatory, Thrombogenic, Lipogenic, Biomarkers in Women With Angina and Metabolic Syndrome.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: University of Florida · Academic / Other
• Sex: Female
• Age: 30 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effects of ranolazine on different markers of cardiometabolic disease in women with stable angina.

Detailed description

Evaluate the ability of ranolazine to favorably modify thrombogenic, inflammatory, lipogenic, oxidative stress and hormonal biomarkers in a relatively short period of time in a group of ethnically diverse women with chronic stable angina and metabolic syndrome.

Conditions

• Stable Angina
• Metabolic Syndrome

Interventions

Type	Name	Description
DRUG	Ranolazine	Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24
OTHER	Placebo	Matching placebo tablets daily for 24 weeks.

Timeline

• Start date: 2015-09-01
• Primary completion: 2018-12-17
• Completion: 2019-05-17
• First posted: 2014-09-30
• Last updated: 2020-04-10
• Results posted: 2020-04-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study